Biotech developing cretostimogene, an oncolytic virus immunotherapy for non-muscle invasive bladder cancer.
Biotech developing cretostimogene, an oncolytic virus immunotherapy for non-muscle invasive bladder cancer.
Has no product to sell yet, so its spending is funded by investors' money, including its 2024 stock-market listing, not by customers. Everything rests on one drug, cretostimogene, a virus engineered to infect and kill bladder tumour cells, and on regulatory approval of it.
Moat: narrow (IP / patents). A differentiated oncolytic-virus mechanism showing strong trial responses in a disease area with limited good options.
Headquarters: Irvine, California, US · Founded: 2019 · Employees: 142
Size CG Oncology (CGON) is a United States Health Care company (Biotechnology) with a market value of $7.15B, the 948th largest of 3,085 United States companies the cockpit tracks. Shares closed at $80.00 on 18 Nov 2026.
Performance Over six months the shares gained 23.5%, against +1.8% for the median peer and -2.2% for the United States market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 183.6% over the last twelve months (peer median +18.9%); the operating margin is -4,293.5% (peer median -11.5%).
Valuation It trades at 1,000.7× enterprise value to sales against a peer median of 14.0× (3rd most expensive of 16).
Short interest Short interest is 10.3% of the free float (30 Oct 2026).
Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $6.17M | $4.04M | $1.14M | $204,000 | $191,000 |
| Revenue growth | — | +255% | +458% | +7% | — |
| Gross profit | -$6.55M | -$652,000 | $1.11M | $187,000 | $176,000 |
| EBITDA | -$261M | -$189M | -$115M | -$55.4M | -$35.2M |
| Net income | -$237M | -$161M | -$88.0M | -$48.6M | -$35.4M |
| Free cash flow | -$189M | -$132M | -$78.9M | -$45.7M | -$29.8M |
| Capital expenditure | $1.89M | $134,000 | $234,000 | $0 | $14,000 |
| Total debt | $9.24M | $7.02M | $238,000 | $826,000 | $16.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| CG Oncology CGON | $7.15B | +24% | +184% | -4,294% | 1,000.7× | n/a |
| Merck & MRK | $340B | +23% | +5% | 18% | 5.7× | 8.3% |
| ImmunityBio IBRX | $7.13B | -17% | +121% | -150% | 44.3× | n/a |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 6.9× | 3.7% |
| UroGen Pharma URGN | $1.46B | -1% | +159% | -12% | 6.3× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CGON | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +29.2% | -9.3% | highest of 21 |
| 6-month return | +23.5% | +1.8% | 9th highest of 21 |
| Distance from 52-week high | -14.8% | -34.3% | 3rd highest of 21 |
| Revenue growth (TTM) | +183.6% | +18.9% | highest of 15 |
| Operating margin | -4,293.5% | -11.5% | 3rd lowest of 16 |
| EV / Sales | 1,000.7× | 14.0× | 3rd most expensive of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CG Oncology CGON | United States | $7.15B | +24% | +184% | -4,294% | 1,000.7× | n/a | n/a |
| Axsome Therapeutics AXSM | United States | $7.05B | -42% | +54% | -19% | 8.0× | n/a | n/a |
| Immunovant IMVT | United States | $6.86B | -7% | n/a | n/a | n/a | n/a | n/a |
| 10x Genomics TXG | United States | $7.51B | +138% | -4% | -11% | 11.3× | 47.2% | +16.6% |
| Twist Bioscience TWST | United States | $7.93B | +117% | +22% | -29% | 16.2× | n/a | n/a |
| Kodiak Sciences KOD | United States | $6.40B | +170% | n/a | n/a | n/a | n/a | n/a |
| Arrowhead Pharmaceuticals ARWR | United States | $6.09B | -44% | -46% | -157% | 14.0× | n/a | n/a |
| Summit Therapeutics SMMT | United States | $8.40B | -41% | n/a | n/a | n/a | n/a | n/a |
| Genscript Biotech 1548.HK | Hong Kong | $8.69B | +133% | +53% | 12% | 9.8× | 36.9% | +19.8% |
| Scholar Rock SRRK | United States | $5.86B | -1% | n/a | -71,732% | 9,900.4× | n/a | n/a |
| ALTEOGEN 196170.KS | South Korea | $8.80B | -56% | +61% | 53% | 35.1× | 24.6% | +38.5% |
| Caris Life Sciences CAI | United States | $5.59B | +24% | +61% | 13% | 5.0× | 18.2% | +61.5% |
| Anthem Biosciences ANTHEM.NS | India | $5.51B | +16% | -1% | 35% | 24.9× | 36.9% | +26.2% |
| Vaxcyte PCVX | United States | $9.26B | +24% | n/a | n/a | n/a | n/a | n/a |
| Krystal Biotech KRYS | United States | $9.34B | +4% | +26% | 48% | 18.0× | 13.1% | +26.0% |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.28B | -1% | -28% | -210% | 5.3× | -6.5% | -10.0% |
| Sichuan Kelun Pharmaceutical 002422.SZ | China | $10.1B | +35% | 0% | 9% | 3.7× | 6.2% | +2.3% |
| Kymera Therapeutics KYMR | United States | $10.3B | +50% | +134% | -396% | 92.4× | n/a | n/a |
| Hangzhou Tigermed Consulting 300347.SZ | China | $4.88B | -2% | +16% | 10% | 4.8× | 25.9% | +16.4% |
| Cogent Biosciences COGT | United States | $4.84B | -16% | n/a | n/a | n/a | n/a | n/a |
| Dianthus Therapeutics DNTH | United States | $4.73B | -5% | -12% | -8,684% | 1,432.1× | n/a | n/a |